Needham & Company LLC Reiterates Buy Rating for Sarepta Therapeutics (NASDAQ:SRPT)
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at Needham & Company LLC in a report issued on Tuesday,Benzinga reports. They currently have a $202.00 price target on the biotechnology company’s stock. Needham & Company LLC’s target price points to a potential upside of 152.59% from […]
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at Needham & Company LLC in a report issued on Tuesday,Benzinga reports. They currently have a $202.00 price target on the biotechnology company’s stock. Needham & Company LLC’s target price points to a potential upside of 152.59% from […]
